NEW YORK, NY / ACCESSWIRE / November 25, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Peabody Energy Corporation (NYSE:BTU)
CONTACT JAKUBOWITZ ABOUT BTU:
https://claimyourloss.com/securities/peabody-energy-corporation-loss-submission-form/?id=11212&from=1
Class Period : April 3, 2017 - October 28, 2019
Lead Plaintiff Deadline : November 27, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had failed to implement adequate safety controls at the North Goonyella mine to prevent the risk of a spontaneous combustion event; (b) the Company failed to follow its own safety procedures; (c) as a result, the North Goonyella mine was at a heightened risk of shutdown; (d) the Company’s low-cost plan to restart operations at the mine posed unreasonable safety and environmental risks; (e) The Australian body responsible for ensuring acceptable health and safety standards, the Queensland Mines Inspectorate, would likely mandate a safer, cost-prohibitive approach; and (f) as a result, there would be major delays in reopening the North Goonyella mine and restarting coal production.
First American Financial Corp. (NYSE:FAF)
CONTACT JAKUBOWITZ ABOUT FAF:
https://claimyourloss.com/securities/first-american-financial-corp-loss-submission-form/?id=11212&from=1
Class Period : February 17, 2017 - October 22, 2020
Lead Plaintiff Deadline : December 24, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company failed to implement basic security standards to protect its customers’ sensitive personal information and data; (2) the Company faced a heightened risk of cybersecurity failure due to its automation and efficiency initiatives; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
Biogen Inc. (NASDAQ:BIIB)
CONTACT JAKUBOWITZ ABOUT BIIB:
https://claimyourloss.com/securities/biogen-inc-loss-submission-form/?id=11212&from=1
Class Period : October 22, 2019 - November 6, 2019
Lead Plaintiff Deadline : January 12, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab’s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer’s disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab’s effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law